News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa® Active Pharmaceutical Ingredient Supplier


12/19/2012 9:12:35 AM

BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Chemport, Inc. as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES